VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

pCMV/ER-PA83
Vaccine Information
  • Vaccine Name: pCMV/ER-PA83
  • Target Pathogen: Bacillus anthracis
  • Target Disease: Anthrax
  • Vaccine Ontology ID: VO_0000876
  • Type: DNA vaccine
  • Antigen: B. anthracis PA
  • pagA gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid: pCMV/myc/ER DNA vaccine plasmid
  • Preparation: For the pCMV/ER PA83 construct, PA83 was cloned into the eukaryotic expression plasmid pCMV/myc/ER. A gene fragment coding for PA83 was amplified by PCR, and the resulting 2205-bp PCR fragment was digested with Pau I and Not I and ligated into the plasmid pCMV/myc/ER (Hahn et al., 2004).
Host Response

Mouse Response

  • Host Strain: BALB/c and A/J
  • Vaccination Protocol: In the first vaccination trial, groups of 5 BALB/c mice were vaccinated on days 0, 14 and 28, with one of the three different PA-expressing plasmid constructs. A fourth group of five negative control mice received pCMV/ myc/ER vector DNA without insert. Each immunization consisted of a dose of approximately 1 mg plasmid DNA, precipitated onto 1.6 mm gold carriers per mouse. The DNA was applied to the shaved abdomen of anesthetized mice using a Helios gene gun. DNA-coated gold particles were discharged with 250 psi helium pressure. In the second vaccination trial, A/J mice were immunized according to the same vaccination protocol, except that the helium pressure for discharge of the DNA-coated gold carriers was increased to 400 psi. The treatment groups in this trial were pSecTag PA83 (13 mice), pCMV/ER PA83 (14 mice), and pCMV/myc/ER as a negative control group (10 mice). In the third vaccination trial, A/J mice were immunized with two shots per immunization using an increased DNA dose of 2.5 mg per shot, which were discharged with 400 psi. Six mice were vaccinated with pCMV/ER PA83 and eight with pSecTag PA83 (Hahn et al., 2004).
  • Immune Response: 26 d after the final immunization, the mice were killed, bled, and the serum samples analyzed for PA-specific antibody titers. All three plasmids induced anti-PA Ig and IgG1 antibody titers. Sera from mice vaccinated with pCMV/ER PA83 had significantly higher anti-PA total immunoglobulin titers than sera from mice vaccinated with pSecTag PA83, or pCMV/ER PA63. The GMT for PA-specific IgG1 of mice immunized with pCMV/ER PA83 was higher but not significantly different than PA-specific IgG1 responses of mice vaccinated with pSecTag PA83 or pCMV/ER PA63. There were no statistically significant differences between the titers of A/J mice immunized with pSecTag PA83 and A/J mice that received the pCMV/ER PA83 plasmid (Hahn et al., 2004).
  • Side Effects: Commercial anthrax vaccines can cause transient side effects, such as local pain and edema, which are probably due to trace amounts of LF and EF. None of these were noted in conjunction with the use of vaccine candidates studied here (Hahn et al., 2004).
  • Challenge Protocol: 14 A/J mice were vaccinated with pCMV/ER PA83, and 13 A/J mice with pSecTag PA83. The negative control group (10 A/J mice) received pCMV/myc/ER plasmid DNA without insert. Ten days after the third immunization, all mice were bled and their individual anti-PA titers were determined by ELISA. The mice of each treatment group were then marked to be challenged with either 10 LD50 of B. anthracis STI spores or 100 LD50 of STI spores. A/J mice immunized with the increased amount of plasmid DNA were all challenged with 100 LD50. After injection with B. anthracis spores, mice were observed for a period of 14 days.Surviving mice were killed and bled. The post-challenge serum samples were also analyzed by anti-PA ELISA and for toxin neutralization titers (Hahn et al., 2004).
  • Efficacy: Vaccination with either pSecTag PA83 or pCMV/ER PA83 showed significant protection of A/J mice against infection with B. anthracis STI spores (Hahn et al., 2004).
References
Hahn et al., 2004: Hahn UK, Alex M, Czerny CP, Bohm R, Beyer W. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination. International journal of medical microbiology : IJMM. 2004 Jul; 294(1); 35-44. [PubMed: 15293452].